JPS60172926A - Healthy food - Google Patents

Healthy food

Info

Publication number
JPS60172926A
JPS60172926A JP59027835A JP2783584A JPS60172926A JP S60172926 A JPS60172926 A JP S60172926A JP 59027835 A JP59027835 A JP 59027835A JP 2783584 A JP2783584 A JP 2783584A JP S60172926 A JPS60172926 A JP S60172926A
Authority
JP
Japan
Prior art keywords
saponin
rice vinegar
health food
diuretic
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP59027835A
Other languages
Japanese (ja)
Other versions
JPH0410448B2 (en
Inventor
Kyoko Noma
野間 恭子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morishita Jintan Co Ltd
Osaka Chemical Laboratory Co Ltd
Original Assignee
Morishita Jintan Co Ltd
Osaka Chemical Laboratory Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morishita Jintan Co Ltd, Osaka Chemical Laboratory Co Ltd filed Critical Morishita Jintan Co Ltd
Priority to JP59027835A priority Critical patent/JPS60172926A/en
Publication of JPS60172926A publication Critical patent/JPS60172926A/en
Publication of JPH0410448B2 publication Critical patent/JPH0410448B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Seeds, Soups, And Other Foods (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

PURPOSE:A healthy food for eliminating fatness, containing a saponin, dregs of unrefined rice vinegar, and a diuretic as active ingredients. CONSTITUTION:A healthy food containing a saponin (saponin obtained from a leguminous plant such as soybean, etc., cucurbitaceous plant such as Gynostemma pentaphyllum Makino, etc.), dregs of unrefined rice vinegar (preferably less of rice vinegar obtained by fermenting rice to give rice vinegar, drying pressed extraction residue, grinding it), and a diuretic (e.g., defatted Coicis Semen, Catalpa, Pounella Spica, etc.) in a blending ratio of 1:5:2-1:100:20. Preferably a dose of saponin is 2-20mg/kg day, dose of dregs of unrefined rice vinegar 10- 250mg/kg, and dose of diuretic 5-50mg/kg, respectively. The healthy food may be blended with other components for various purposes. Addition of ISAGORU (edible fiber) is especially preferable because it provides a person who eats it with a feeling of fullness with its small amount and prevents excess intake of calorie. A biscuit, tablet, powder, etc. may be used as the dosage form.

Description

【発明の詳細な説明】 本発明は健康食品、より詳しくは、肥満防止または解消
を可能にする健康食品、特にビスケットに関する。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to health foods, more particularly to health foods that make it possible to prevent or eliminate obesity, especially biscuits.

従来、種々の健康食品が痩身等の目的で市販されている
が、その多くのものは配合されている甘味料等のカロリ
ーを抑え、カロリーの取り過ぎを防止して、痩せようと
するものである。しかしながら、実際にはビスケット等
の間食類のカロリーを抑えたところで、他の食品で多く
のカロリーを摂取する場合が多く、肥満解消には役立た
ない事が多い。
Conventionally, various health foods have been commercially available for purposes such as weight loss, but many of them are designed to reduce the amount of calories contained in sweeteners, etc., to prevent people from consuming too many calories, and to help people lose weight. be. However, in reality, even if the calorie content of snack foods such as biscuits is reduced, many calories are ingested from other foods, and this is often not useful for alleviating obesity.

また、大豆サポニン等の脂肪の分解を促進す物質の添加
により、積極的に肥満を防止する試みもなされているが
、肥満は種々の要因で起るものであり、単一成分の添加
のみではその効果が十分上がらないのが一般的である。
In addition, attempts have been made to actively prevent obesity by adding substances that promote fat breakdown, such as soybean saponin, but obesity is caused by various factors, and adding only a single ingredient is not enough. Generally, the effect is not sufficiently increased.

本発明者等は肥満の種々の要因を検討し、その要因の全
てを抑制し得る健康食品を研究の結果、サポニン、米酢
モロミおよび利尿剤を有効成分として含有する健康食品
が有効に肥満解消することを見出した。
The inventors of the present invention have examined various causes of obesity and researched health foods that can suppress all of the factors. As a result, a health food containing saponin, rice vinegar moromi, and diuretics as active ingredients effectively alleviates obesity. I found out what to do.

本発明(ご用いるサポニンは、ダイズ、アズキ。The present invention (saponins used are soybean and azuki bean).

オウギ等のマメ科の植物、ポウブラ、カポチャ。Plants of the legume family such as Aspergillus, paubra, and kapocha.

アマチャヅル等のウリ科植物、その他、朝鮮人参。Cucurbitaceae plants such as Jiaogulan, other plants, and Korean ginseng.

サルサの根、キキョウ根、甘草等の植物から得られるも
のであってよい。好ましくは大豆サポニンである。サポ
ニンは脂肪の分解を促し、余分な脂肪の合成吸収を抑制
し、体内に過酸化脂質ができるのを防ぐ効果を有する。
It may be obtained from plants such as salsa root, bellflower root, and licorice root. Preferred is soybean saponin. Saponin has the effect of promoting the decomposition of fat, suppressing the synthesis and absorption of excess fat, and preventing the formation of lipid peroxide in the body.

サポニンは通常知られているいかなる製法により得ても
よい。例えば、原料を乾燥粉砕し、11−ヘキサン等の
脂溶性溶媒を用い脱脂し、次いで低級脂肪族アルコール
で加熱抽出後、n−ブタノール:水(1:1)の混液で
処理し、溶媒を減圧下で留去し、残留物に少量のメタノ
ールを加えて溶解する。この液を多量のエーテル中に加
え、沈澱物を生じさせ水飽和n−ブタノールで処理し、
可溶部を減圧蒸留し、溶媒を除去し残留物をn−ブタノ
ール:水(1:1)の混液で分配後、水移行部をシリカ
ゲルカラムクロマトグラフィー(溶出溶媒: ’y o
ロホルムーメタノールー水)にて分別する等の方法によ
り得られた粉末状のものを用いる。
Saponin may be obtained by any commonly known manufacturing method. For example, the raw material is dry-pulverized, degreased using a fat-soluble solvent such as 11-hexane, then heated and extracted with a lower aliphatic alcohol, treated with a mixture of n-butanol and water (1:1), and the solvent is removed under reduced pressure. The residue was distilled off at the bottom and dissolved by adding a small amount of methanol. This solution was added to a large amount of ether to form a precipitate and treated with water-saturated n-butanol,
The soluble part was distilled under reduced pressure, the solvent was removed, and the residue was distributed with a mixture of n-butanol and water (1:1).The water-transferred part was subjected to silica gel column chromatography (elution solvent:
A powder obtained by a method such as fractionation with (loform-methanol-water) is used.

サポニンの人への投与量は、体重1即あたり、1日2〜
20■である。1■以下であると、減量効果が生じず、
経口的に毒性は弱いが、大量に投与すると、アルコール
代謝促進等の副作用が生じる。
The dosage of saponin for humans is 2 to 2 times a day per 1 body weight.
It is 20■. If it is less than 1■, there will be no weight loss effect,
It has low toxicity orally, but when administered in large quantities, side effects such as promotion of alcohol metabolism occur.

米酢モロミは脂質の合成吸収を抑制し、便通改善作用が
ある。また、血液循環がよくなる作用も有する。
Rice vinegar moromi suppresses lipid synthesis and absorption and has the effect of improving bowel movements. It also has the effect of improving blood circulation.

米酢モロミは、一般に米を醗酵させ、米酢を生産した後
、圧搾抽出残渣を乾燥し、粉砕する等の方法で製造され
る米酢粕が好ましい。
Rice vinegar moromi is preferably rice vinegar lees, which is generally produced by fermenting rice to produce rice vinegar, then drying and pulverizing the pressed extraction residue.

米酢モロミの投与量は10〜250 ’Q/に9の範囲
が好ましい。5m9以下であると減量効果が生じず、5
00m7を越えると効果は減少していく。
The dosage of rice vinegar moromi is preferably in the range of 10 to 250'Q/9. If it is less than 5m9, there will be no weight loss effect, and
The effect decreases as the distance exceeds 00m7.

利尿剤の例としては脱脂ヨクイニン、キササゲカゴソウ
、ゴシツ、゛ノウハクヒ、タイソウ、カフェイン等が例
示される。好ましくは脱脂ヨクイニンである。脂肪合成
阻害作用を有するものが好ましい。脱脂ヨクイニンの製
法は一般にノ1トムギの種皮を除いた後、20メツシュ
程度に粉砕し、これを、11−ヘキサン等の脂溶性溶媒
を用いて脱脂し、残渣を乾燥粉砕する方法等が例示され
る。
Examples of diuretics include defatted yokuinin, kasapagekagosou, goshitsu, ``nouhakuhi'', japanese radish, and caffeine. Preferably it is defatted Yokuinin. Those having a fat synthesis inhibiting effect are preferred. The general method for producing defatted Yokuinin is to remove the seed coat of No. 1 tome, grind it into about 20 mesh pieces, defatte it using a fat-soluble solvent such as 11-hexane, and dry and grind the residue. Ru.

利尿剤の投与m、としては5〜50■/KIiの範囲が
好ましい。2■/に9以下であると減量効果か現われな
い。
The dosage m of the diuretic is preferably in the range of 5 to 50 μ/KIi. If it is less than 9/2, no weight loss effect will be seen.

サポニン:米酢モロミ:脱脂ヨクイニンの配合比は1:
5:2〜1:100二20の範囲が好ましい。
The blending ratio of saponin: rice vinegar moromi: defatted Yokuinin is 1:
A range of 5:2 to 1:100-20 is preferred.

本発明健康食品には種々の目的で他の成分を配合しても
よい。例えば、難消化性多糖の一種として高アミロース
スターチ、食物繊維の一種である水分により膨満感を与
えるイサコール、その他低カロリーの甘味増量剤(粉末
の還元麦芽糖、還元麦芽糖水飴、キシロース、ポリデキ
ストローズ等)が例示される。
The health food of the present invention may contain other ingredients for various purposes. For example, high amylose starch is a type of indigestible polysaccharide, isacol is a type of dietary fiber that causes a feeling of fullness due to water content, and other low-calorie sweet bulking agents (reduced maltose powder, reduced maltose starch syrup, xylose, polydextrose, etc.) ) is exemplified.

特にイサゴールを本発明健康食品に配合することは、被
食者に少量で満腹感を与え、間食その曲の食品によるカ
ロリーの取り過きを防止するので特に好ましい。
In particular, it is particularly preferable to incorporate isagol into the health food of the present invention because it gives the recipient a feeling of fullness with a small amount and prevents them from consuming too many calories from snack foods.

また、本発明健康食品にはビタミンやその他の滋養物、
あるいは香料等を内容物とするマイクロカプセルを配合
するのが好ましい。特にビスヶ・ント等のオーブンで焼
成することを要する食品に香料あるいはビタミンを直接
配合すると熱分解等により分解するおそれがあるので、
マイクロカプセルによる配合が好ましい。
The health food of the present invention also contains vitamins and other nutrients,
Alternatively, it is preferable to incorporate microcapsules containing perfume or the like. In particular, if flavorings or vitamins are directly added to foods that require baking in an oven, such as biscuits, etc., there is a risk of decomposition due to thermal decomposition, etc.
Preference is given to formulation in microcapsules.

マイクロカプセルの製法としては従来公知のいか−なる
方法でもよいが、特に特開昭56−49154号に記載
のものが適している。
Although any conventionally known method may be used for manufacturing the microcapsules, the method described in JP-A-56-49154 is particularly suitable.

本発明の健康食品の例としては、ビスケット、錠剤、散
剤1、顆粒剤、欠削、始等が挙げられる。
Examples of the health food of the present invention include biscuits, tablets, powders 1, granules, chips, and the like.

本発明の健康食品を摂取すると、種々の部位で脂肪組織
部位の重量が低下し、肥満が解消し、それに併ってコレ
ステロールの減少もみられる。
When the health food of the present invention is ingested, the weight of adipose tissue in various regions is reduced, obesity is eliminated, and cholesterol is also reduced.

また、水分により膨張する食物繊維(イサゴール等)を
配合すると、例えばビスケン13枚程度で十分な満腹感
が得られ、1日の食事の1食にビスケットを用いるのみ
で、無理なく肥満が解消され、しかも他の食品でカロリ
ーを取り過ぎる可能性も殆んどない。
Additionally, if you incorporate dietary fiber that expands with water (such as isagol), you can feel full with just 13 biscuits, and eating just one biscuit a day can easily eliminate obesity. , and there's little chance of getting too many calories from other foods.

本発明を実施例により更に詳細に説明する。The present invention will be explained in more detail with reference to Examples.

実施例1 マウス)こゴールドチオグルコース(C,old tb
i −oglucose)を投与し、肥満マウスを作成
し、マウスの肥満に及はす米酢粕単独1本発明添加剤(
大豆サポニン、米酢粕およびヨクイニノ、以下合剤とい
う)およびヨクイニン単独の作用と、ラットK 5tr
eptozotocin(インシュリン分泌B細胞破壊
)を投与し、糖尿病ラットを作成し、糖尿病ラットに及
ぼす米酢粕、合剤およびヨクイニンの作用について実験
を行った。
Example 1 Mouse) Gold thioglucose (C, old tb)
Obese mice were created by administering rice vinegar lees alone to the additive of the present invention (i-oglucose) to create obese mice.
Effects of soybean saponin, rice vinegar lees and Yokuinino (hereinafter referred to as a combination) and Yokuinin alone, and rat K 5tr
Eptozotocin (insulin-secreting B cell destruction) was administered to create diabetic rats, and experiments were conducted to examine the effects of rice vinegar lees, the combination drug, and Yokuinin on diabetic rats.

A、実験材料 動物はtcit系雌のマウス、体重25 g、 wis
tar系雄のラット、体重200gのものを静岡実験動
物研究所より購入し、約5日間予備飼育を行った後実験
に供した。
A, Experimental material: The animal is a tcit female mouse, weighing 25 g, wis
Male tar rats weighing 200 g were purchased from the Shizuoka Laboratory for Experimental Animals and preliminarily bred for about 5 days before being used in experiments.

Gold thioglucoseはSl、GUMA社
製、米酢粕。
Gold thioglucose is Sl, manufactured by GUMA, rice vinegar lees.

合剤およびヨクイニンは、森下仁月(株)!8!てあっ
た。
The combination drug and Yokuinin are manufactured by Hitoshi Morishita Co., Ltd.! 8! There was.

マウス飼育の配合飼料は、次の様な配合割合である。The blended feed for raising mice has the following proportions.

重量饅 カゼイン 15 コーンスターチ 55 コーンオイル 25 サルト混合物 4 ビタミン混合物 1 ビタミンA 3000 lU 30%コリンクロリド 200”’? 上記の配合飼料に被験薬物を混合してマウスに投与した
Weighted casein 15 Corn starch 55 Corn oil 25 Salto mixture 4 Vitamin mixture 1 Vitamin A 3000 lU 30% choline chloride 200''? The above-mentioned compounded feed was mixed with the test drug and administered to mice.

又、ラツ目こはオリエンタル酵母社製ラット用粉末飼料
に被験薬物を混合して投与した。
In addition, the test drug was mixed with powdered rat feed manufactured by Oriental Yeast Co., Ltd. and administered to the rats.

B、実験方法 1) Gold Lhioglucose 投与による
肥満マウスに及はす米酢粕、合剤およびヨクイニンの作
用:ICR系雌のマウスを5日間予備飼育し、健康で色
並みの良いマウスを用いて実験を行った。
B. Experimental method 1) Effects of rice vinegar lees, combination drug, and Yokuinin on obese mice due to Gold Lhioglucose administration: ICR female mice were preliminarily bred for 5 days, and experiments were conducted using healthy and well-colored mice. I did it.

即ち、マウスにGold Lhioglucose O
,6/Ky (体重)を腹腔内投与し、7週間配合飼料
で飼育後層殺し、ただちに血液、肝傍子宮脂肪組織及び
腸管を採取した。
That is, mice were treated with Gold Lhioglucose O.
, 6/Ky (body weight) was administered intraperitoneally to the rats, and after being fed a mixed diet for 7 weeks, they were sacrificed, and blood, parahepatic uterine adipose tissue, and intestinal tract were immediately collected.

実験群は次の通りとした。The experimental groups were as follows.

a)正常群−=・−・Gold Llliogluco
se を投与せず、普通食(固型食)で飼育した。
a) Normal group -=・-・Gold Llliogluco
The mice were fed normal food (solid food) without administering se.

b)肥満群・−−Gold thioglucose 
を投与し、配合飼料のみで投与した。
b) Obesity group --- Gold thioglucose
were administered, and the compound feed alone was administered.

C)米酢粕投与群・−−−−−Gold tbiogl
 ucoseを投与し、配合飼料に米酢粕5!/に’!
および1!/KV摂取量に混合して飼育した。
C) Rice vinegar lees administration group---Gold tbiogl
Administer ucose and add 5 rice vinegar lees to the mixed feed! /ni'!
and 1! /KV intake.

d)合剤(Crude 5oyasaponin)投与
群−−−−−−Golclrbic+glucoseを
投与し、配合餌aをこ合剤(Crude 5oyasa
ponin IQ□n1gA!/)オ、1: ヒ合剤(
C,S 50 my/Ky )摂取用混合して飼育した
d) Combined drug (Crude 5oyasaponin) administration group-----Golclrbic+glucose was administered, and compound feed a was administered to the mixed drug (Crude 5oyasaponin).
ponin IQ□n1gA! /) E, 1: Hypoallergenic agent (
C, S 50 my/Ky) were mixed and raised for intake.

e)ヨクイニン投与群・−・・−Gold t、bio
glucoseを投与し、配合飼料にヨクイニン1g /に? 、 0.5 f/KIJ:ヒ0.1 !/に?
摂取量を加えて飼育した。
e) Yokuinin administration group --- Gold t, bio
Administer glucose and add 1g/yokuinin to the mixed feed? , 0.5 f/KIJ: Hi 0.1! /to?
The animals were fed with additional intake.

以上の各群のマウスを7週間飼育した。Mice in each of the above groups were kept for 7 weeks.

飼育期間中、エサ及び水は自由に与え1週間に1変長食
量及び体重の測定を行った。
During the rearing period, food and water were provided ad libitum, and food intake and body weight were measured once a week.

マウスは実験に当たり摂食状態とし、頚動脈より採血し
、開腹後直ちに肝、傍子宮脂肪組織及び腸管を摘出した
。又、肝及び傍子宮脂肪組織重量を測定した。
The mice were kept in a fed state for the experiment, blood was collected from the carotid artery, and the liver, parauterine adipose tissue, and intestinal tract were removed immediately after laparotomy. In addition, the weights of liver and parauterine adipose tissue were measured.

2)ストレプトシトシフ (Streptozotoc
in)投与3こよる糖尿病ラットにおよぼす米酢粕9合
剤およびヨクイニンの作用: WisLar系雄のラットを1週間予備飼育し、健康で
毛並の良いラットを用いて実験を行った。
2) Streptozotoc
in) Effects of rice vinegar lees 9 mixture and Yokuinin on diabetic rats after administration 3: WisLar male rats were preliminarily bred for one week, and experiments were conducted using healthy rats with good fur.

即ち、ラットを14時間絶食しく但し、水は自由に摂食
させた)、尾静脈より5trepLozoLoc −i
n を651n97にg当たりラットに投与し、5日間
固型飼料で飼育し、尿検査を行い糖尿病になっているラ
ットを用いて薬物投与を行った。薬物を5週間投与し、
血液及び肝を採取した。但し屠殺前14時間は絶食状態
とした(水は自由に摂取させた)。
That is, rats were fasted for 14 hours but allowed access to water ad libitum), and 5trepLozoLoc-i was administered via the tail vein.
N was administered to rats per gram at 651n97, fed on chow for 5 days, and a urine test was performed. The rats were diabetic and administered the drug. The drug was administered for 5 weeks,
Blood and liver were collected. However, the animals were kept in a fasted state for 14 hours before slaughter (water was freely available).

投与群は以下の通りとした。The administration groups were as follows.

a)正常群−−−−−−5trcptozotocin
を投与せず、固型飼料で飼育した。
a) Normal group----5trcptozotocin
The animals were raised on solid feed without being administered.

b)糖尿病群−−−−−−5treptozotoci
n を投与し、粉末飼料で飼育した。
b) Diabetic group----5treptozotoci
n and fed powdered feed.

C)米酢軸群−−−−−−5Lreptozotoci
n を投与し、粉末飼料に米酢粉を5f!/に9および
1!/に9<摂取量)混合し投与した。
C) Rice vinegar axis group----5Lreptozotoci
Administer n and add 5f of rice vinegar powder to powdered feed! / to 9 and 1! /9<intake amount) and administered.

d)合剤群−−−−−−5treptozotocin
を投与し7、粉末飼料に合剤(Crude 5oyas
aponin100 wtg/KV)オ、1: ヒ(C
,S 50”’W/に?) 摂取量混合し飼育した。
d) Combination drug group----5treptozotocin
7, and a mixture (Crude 5 oyas) was added to powdered feed.
aponin100 wtg/KV) O, 1: Hi (C
, S 50'''W/?) were reared with mixed intakes.

e)ヨクイニン群−=−3treptozotocin
を投与し、粉末飼料にヨクイニンIQ/Kp、0.5!
/に9および0.1g/Kl摂取量)混合し、飼育した
e) Yokuinin group -=-3treptozotocin
was administered, and the powdered feed had a Yokuinin IQ/Kp of 0.5!
/ 9 and 0.1 g/Kl intake) and reared.

J 血液の血糖、インスリン、トランスアミナーゼ及び
脂質、又は肝脂質の測定: 0中性脂肪(”I’riglyceride)・−−−
−−”ll’riglyccride B−test 
(和光)0過酸化脂質(Lipoperoxide)・
−・・−Lipoperoxide−test (和光
)O総コレスフ o−ル(Total Cholest
erol )−Cholesterol B −tes
tO血糖(Glucose) −−−−−−Gluco
se B−test (和光)0トランスアミナーゼ(
GO”I’、GPT)・・・・・・S・TA−test
(和光) Oインスリン(Insul in)・・・・・・EIA
法(MBL製) oNEFA・・−NEFA−test (和光)Oリン
脂質(PIIO!IPIIOI 1pid)・・・・・
・PIIO8L)11011pids−test (和
光)4)小腸における形態学的変化: マウスを屠殺後、直ちに小腸を十二指腸と空回隅部に分
けて摘出し、腸内害物を0.9%NaCj’で2回洗浄
し、各腸管について幽門部から4〜6c+++の部位を
用いて観察資料とした。摘出した腸管は2.5%ゲルタ
ールアルデヒドで氷中固定した後、導電染色を行い、臨
界点乾燥(日立[Ict’−1)、白金蒸着(日立IB
−5)後に日立S−50OA走査電子顕微鏡を用いて観
察した。
J Measurement of blood glucose, insulin, transaminases and lipids, or liver lipids: 0 Neutral fat ("I'riglyceride)" ---
--"ll'riglycride B-test
(Wako) 0 Lipoperoxide
-・・-Lipoperoxide-test (Wako) Total Cholesf
erol )-Cholesterol B-tes
tO blood sugar (Glucose) -------Gluco
se B-test (Wako) 0 transaminase (
GO"I', GPT)...S・TA-test
(Wako) O Insulin...EIA
Method (manufactured by MBL) oNEFA...-NEFA-test (Wako) O phospholipid (PIIO! IPIIOI 1pid)...
・PIIO8L) 11011pids-test (Wako) 4) Morphological changes in the small intestine: Immediately after sacrificing the mouse, the small intestine was divided into the duodenum and the corner of the gyrus and removed, and intestinal harmful substances were removed with 0.9% NaCj'. The intestine was washed twice, and a site 4 to 6c+++ from the pylorus was used as observation material for each intestinal tract. The excised intestinal tract was fixed in ice with 2.5% geltaraldehyde, conductive staining was performed, critical point drying (Hitachi [Ict'-1), platinum deposition (Hitachi IB
-5) It was then observed using a Hitachi S-50OA scanning electron microscope.

5)腸粘膜酵素活性の測定: 小腸を十二指腸と空回股部分とに分けて予め0.9%N
aC/で2回洗浄後、反転し粘膜部分を藤田の方法に従
ってかきとり、0.9%NaCj7で10%ホモジネー
ト液を作製し、酵素活性測定の試料とした。Malto
se 及び5ucrase 活性はDahlguist
 の方法を用いて測定した。
5) Measurement of intestinal mucosal enzyme activity: Divide the small intestine into the duodenum and the jejunum and preliminarily add 0.9% N.
After washing twice with aC/, the membrane was inverted and the mucosal part was scraped off according to Fujita's method, and a 10% homogenate solution was prepared with 0.9% NaCj7, which was used as a sample for enzyme activity measurement. Malto
se and 5ucrase activities were determined by Dahlguist.
It was measured using the method of

上記結果を表−1に示す。The above results are shown in Table-1.

表−1から明らかなように、ヨクイニン、米酢粕単独で
も肥満の抑制作用があるものの、合剤のようにバランス
良く肥満を抑制する効果はみられない。
As is clear from Table 1, although Yokuinin and rice vinegar lees alone have an anti-obesity effect, they do not have the well-balanced anti-obesity effect like a combination drug.

実施例2 以下に示す方法でビスケットを調製した。Example 2 Biscuits were prepared by the method shown below.

成分A 無塩マーガリン 100 シヨートニング 50 粉末マルチ 275 ノくニラエツセンス 25 卵(全卵)135 成分B 大豆サポニン 1 米酢モロミ 20 脱脂ヨクイニン 20 イサゴール 、 120 脱脂粉乳 125 塩 5 ベーキングパウダー 10 ワニラコートン 10 成分C薄力粉 250 高アミローススターチ 250 計 1396 成分A中の無塩マーガリン、ショートニングをクリーム
状に練り、粉末マルチを加えて均一にした後、溶き卵、
バニラエツセンスを加えて混合した。次いで、上記成分
Bをふるい合わせたものを加えて練り合わせ、成分Cを
加えて練り合わせた。
Ingredients A unsalted margarine 100 shyotoning 50 powdered mulch 275 cm licked rice 25 eggs (all eggs) 135 ingredients B soy saponin 1 Rice vinegar 20 oakinin 20 isagor, 120 degreasing pour milk 125 salt 5 baking powder 10 crab coaton 10 ingredients c Skill flour 250 High amylose starch 250 Total 1396 Knead the unsalted margarine and shortening in ingredient A into a cream, add powdered mulch to make it homogeneous, then add beaten eggs,
Add vanilla essence and mix. Next, a sieved mixture of the above component B was added and kneaded, and component C was added and kneaded.

これを打ち粉しながら、5mmの厚さに伸ばし型で抜き
、150℃のオーブンで15分焼いた。
While dusting with flour, it was rolled out to a thickness of 5 mm, cut out with a mold, and baked in an oven at 150°C for 15 minutes.

得られたビスケットを5人のモニターに2ケ月間投与し
た結果、全てのモニターで体重、胸まわり、ウェスト、
ヒップおよび太もも回りの減少がみられた。モニターの
減少率=(測定時の値−開始時の値)/開始時の値(X
100)の変化を第1〜5図に示す。投与量は昼食特に
上記ビスケット3枚であった。全てのモニターにおいて
空腹感はなかった。
As a result of administering the obtained biscuits to five monitors for two months, all monitors showed changes in body weight, chest circumference, waist circumference,
A decrease in hip and thigh circumference was observed. Monitor reduction rate = (value at measurement - value at start) / value at start (X
100) are shown in Figures 1-5. The dosage was lunch, specifically the three biscuits mentioned above. There was no feeling of hunger on all monitors.

実施例3 以下に示す材料を用いて香料カプセル入りビスケットを
調製した。
Example 3 A biscuit containing flavor capsules was prepared using the materials shown below.

材料 (約110枚分) 重量(gン 成分A 無塩マーガリン 100 シヨートニング 50 粉末マルチ 275 卵(全卵) 135 香料カプセル(マイクロカプセル)56成分B 大豆サ
ポニン 1 米酢モロミ 20 脱脂ヨクイニン 20 イサゴール 120 脱脂粉乳 125 塩 5 ベーキングパウダー 10 成分C薄力粉 250 高アミローススターチ 250 計 1417 製法は実施例2と同様であった。
Materials (approx. 110 sheets) Weight (grams) Ingredient A Unsalted margarine 100 Shyotoning 50 Powdered mulch 275 Egg (whole egg) 135 Fragrance capsule (microcapsule) 56 Ingredient B Soybean saponin 1 Rice vinegar moromi 20 Defatted Yokuinin 20 Isagol 120 Defatted Milk powder 125 Salt 5 Baking powder 10 Component C soft flour 250 High amylose starch 250 Total 1417 The manufacturing method was the same as in Example 2.

【図面の簡単な説明】[Brief explanation of the drawing]

第1図〜第5図はモニターテストの結果を表わす図であ
る。第1図は体重の減少率、第2図は胸まわりの減少率
、第3図はウェストの減少率、第4図はヒップの減少率
および第5図は太ももの減少率を表わすグラフである。 特許出願人 株式会社大阪薬品研究所
1 to 5 are diagrams showing the results of monitor tests. Figure 1 is a graph showing the rate of decrease in body weight, Figure 2 is the rate of decrease in chest circumference, Figure 3 is the rate of decrease in waist, Figure 4 is the rate of decrease in hips, and Figure 5 is a graph showing the rate of decrease in thighs. . Patent applicant Osaka Pharmaceutical Research Institute Co., Ltd.

Claims (1)

【特許請求の範囲】 1、サポニン、米酢モロミおよび利尿剤を有効成分とし
て含有する健康食品。 2、サポニンが大豆サポニンである第1項記載の健康食
品。 3、利尿剤が脱脂ヨクイニンである第1項記載の健康食
品。 4、健康食品がビスケットである第1項記載の健康食品
。 5、サポニン、米酢モロミ、利尿剤および食物繊維を含
有する健康食品。 6、サポニンが大豆サポニンである第5項記載の健康食
品。 7、利尿剤が脱脂ヨクイニンである第5項記載の健康食
品。 8、食物繊維がイサゴールである第5項記載の健康食品
。 9、健康食品がビスケットである第5項記載の健康食品
。 10、サポニン、米酢モロミ、利尿剤および食物繊維と
ともに、ビタミンまたは栄養剤等を内容物とするマイク
ロカプセルを含有する健康食品。 11、サポニンが大豆サポニンである第10項記載の健
康食品。 12、利尿剤が脱脂ヨクイニンである第10項記載の健
康食品。 13、食物繊維がイサゴールである第10項記載の健康
食品。 14、健康食品がビスケットである第10項記載の健康
食品。
[Claims] 1. A health food containing saponin, rice vinegar moromi, and a diuretic as active ingredients. 2. The health food according to item 1, wherein the saponin is soybean saponin. 3. The health food according to item 1, wherein the diuretic is defatted Yokuinin. 4. The health food according to item 1, wherein the health food is a biscuit. 5. Health food containing saponin, rice vinegar moromi, diuretic and dietary fiber. 6. The health food according to item 5, wherein the saponin is soybean saponin. 7. The health food according to item 5, wherein the diuretic is defatted Yokuinin. 8. The health food according to item 5, wherein the dietary fiber is isagol. 9. The health food according to item 5, wherein the health food is a biscuit. 10. A health food containing microcapsules containing saponin, rice vinegar moromi, diuretics, dietary fiber, and vitamins or nutrients. 11. The health food according to item 10, wherein the saponin is soybean saponin. 12. The health food according to item 10, wherein the diuretic is defatted Yokuinin. 13. The health food according to item 10, wherein the dietary fiber is isagol. 14. The health food according to item 10, wherein the health food is a biscuit.
JP59027835A 1984-02-15 1984-02-15 Healthy food Granted JPS60172926A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP59027835A JPS60172926A (en) 1984-02-15 1984-02-15 Healthy food

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59027835A JPS60172926A (en) 1984-02-15 1984-02-15 Healthy food

Publications (2)

Publication Number Publication Date
JPS60172926A true JPS60172926A (en) 1985-09-06
JPH0410448B2 JPH0410448B2 (en) 1992-02-25

Family

ID=12231988

Family Applications (1)

Application Number Title Priority Date Filing Date
JP59027835A Granted JPS60172926A (en) 1984-02-15 1984-02-15 Healthy food

Country Status (1)

Country Link
JP (1) JPS60172926A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0680959U (en) * 1994-02-07 1994-11-15 矢野技研株式会社 Flow path switching structure
WO1999063979A3 (en) * 1998-06-08 2000-03-16 Sambasiva R Chavali Inhibition of δ-9-desaturase activity by saponins
JP2002275078A (en) * 2001-01-11 2002-09-25 Kanebo Ltd Lipolysis promoter
US8071141B2 (en) * 2000-12-12 2011-12-06 Kaneka Corporation Compositions for preventing or ameliorating multiple risk factor syndromes
CN103976330A (en) * 2014-05-26 2014-08-13 江苏大学 Marinade for brewing vinegar-processed coix seeds and brewing method

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0680959U (en) * 1994-02-07 1994-11-15 矢野技研株式会社 Flow path switching structure
WO1999063979A3 (en) * 1998-06-08 2000-03-16 Sambasiva R Chavali Inhibition of δ-9-desaturase activity by saponins
US8071141B2 (en) * 2000-12-12 2011-12-06 Kaneka Corporation Compositions for preventing or ameliorating multiple risk factor syndromes
JP2002275078A (en) * 2001-01-11 2002-09-25 Kanebo Ltd Lipolysis promoter
CN103976330A (en) * 2014-05-26 2014-08-13 江苏大学 Marinade for brewing vinegar-processed coix seeds and brewing method

Also Published As

Publication number Publication date
JPH0410448B2 (en) 1992-02-25

Similar Documents

Publication Publication Date Title
Wani et al. Fenugreek: A review on its nutraceutical properties and utilization in various food products
EP1065945B1 (en) Method for producing a fat mixture
Srinivasan Fenugreek (Trigonella foenum-graecum): A review of health beneficial physiological effects
US5654001A (en) Dietary lipid digestion-absorption inhibitory agents and ingesta
TWI329516B (en) Composition for preventing or ameliorating multiple risk factor syndromes and visceral fat-type obesity
KR100813175B1 (en) Lipolysis booster and its food preparation for prevention and improvement of obesity
US6652891B2 (en) Co-enzyme Q10 dietary supplement
EP0826369B1 (en) Therapeutic use of dioxabicyclo (3.3.0)octane compounds
WO2011077800A1 (en) Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and foods and beverages
US5268367A (en) Composition and method for lowering blood level of LDL-cholesterol
CN108391785A (en) A kind of functionality meal replacement powder and its manufacture craft and application
KR19990063480A (en) Compositions Effective in Reducing Obesity and Foods and Beverages Containing the Same
US20110033561A1 (en) Use of phytoecdysones in the preparation of a composition for acting on the metabolic syndrome
EP1090635B1 (en) Use of ferulic acid for treating hypertension
JP2008266223A (en) Formulation for ameliorating excessive sensitivity to cold
JPH0458847A (en) Obesity-resistant fat and oil and obesity-resistant food
JPS60172926A (en) Healthy food
WO2005027949A1 (en) Turmeric-containing composition
KR100237974B1 (en) Confectionery composition containing principally the bark of mulberry tree for diabetic
JP3807464B2 (en) Anti-obesity agent
Kakkar et al. How Can Flaxseed be Utilized as Functional Food
HU225983B1 (en) Bakery product containing more oleaginous plant-seed and oleaginous plant-seed application for producing of bakery product with healing power
KR100293890B1 (en) Food composition for control of body weight and blood sugar prepared by using Dong-A Green Juice and its residue
Dhull et al. Fenugreek (Trigonella foenum-graecum): Nutritional, health properties and food uses
JPWO2008111651A1 (en) Metabolic syndrome improving or preventing agent, and beverage, food and feed containing the same